Ductal Carcinoma in situ: Underestimation of Percutaneous Biopsy and Positivity of Sentinel Lymph Node Biopsy in a Brazilian Public Hospital

References

• SilversteinMJ, PollerDN, WaismanJR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 1995;345:1154–1157. doi:10.1016/S0140-6736(95)90982-67723550
   PubMed Web of Science ®Google Scholar
• TrentinC, DominelliV, MaisonneuveP, et al. Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases. Breast. 2012;21(5):635–640. doi:10.1016/j.breast.2012.06.00922795363
   PubMed Web of Science ®Google Scholar
• JansenSA. Ductal carcinoma in situ: detection, diagnosis, and characterization with magnetic resonance imaging. Semin Ultrasound CT MR. 2011;32(4):306–318. doi:10.1053/j.sult.2011.02.00721782121
   PubMed Web of Science ®Google Scholar
• CarterBA, JensenRA, SimpsonJF, PageDL. Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol. 2000;113(2):259–265. doi:10.1309/7EF8-F1W7-YVNT-H8H510664628
   PubMed Web of Science ®Google Scholar
• TvedskovTF, JensenMB, KromanN, BalslevE. Iatrogenic displacement of tumor cells to the sentinel node after surgical excision in primary breast cancer. Breast Cancer Res Treat. 2012;131:223–229. doi:10.1007/s10549-011-1720-y21850395
   PubMed Web of Science ®Google Scholar
• BassettLW, MahoneyMC, AppleSK. Interventional breast imaging: current procedures and assessing for concordance with pathology. Radiol Clin North Am. 2007;45(5):881–894. doi:10.1016/j.rcl.2007.06.01017888775
   PubMed Web of Science ®Google Scholar
• LeeJM, KaplanJB, MurrayMP, et al. Underestimation of DCIS at MRI-guided vacuum-assisted breast biopsy. AJR Am J Roentgenol. 2007;189(2):468–474. doi:10.2214/AJR.07.217217646475
   PubMed Web of Science ®Google Scholar
• WickerhamDL. Ductal carcinoma-in-situ. J Clin Oncol. 2001;19(suppl):98S–100S.11560982
   PubMed Web of Science ®Google Scholar
• SilversteinMJ, LagiosMD, CraigPH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996;77:2267–2274. doi:10.1002/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V8635094
   PubMed Web of Science ®Google Scholar
• KimT, GiulianoAE, LymanGH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106(1):4–16. doi:10.1002/cncr.2156816329134
   PubMed Web of Science ®Google Scholar
• WilkeLG, McCallLM, PostherKE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491–500. doi:10.1245/ASO.2006.05.01316514477
   PubMed Web of Science ®Google Scholar
• FeldmanSM, KragDN, McNallyRK, MoorBB, WeaverDL, KleinP. Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy. J Am Coll Surg. 1999;188:248–254. doi:10.1016/S1072-7515(98)00306-810065813
   PubMed Web of Science ®Google Scholar
• WanZB, GaoHY, WeiL, et al. Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion. Medicines. 2018;97(44):e13055. doi:10.1097/MD.0000000000013055
   Google Scholar
• AllredDC, AndersonSJ, PaikS, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268–1273. doi:10.1200/JCO.2010.34.014122393101
   PubMed Web of Science ®Google Scholar
• RosesRE, PaulsonEC, SharmaA, et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1386–1389. doi:10.1158/1055-9965.EPI-08-110119383888
   PubMed Web of Science ®Google Scholar
• DaltoéRD, MadeiraKP, de CarvalhoAA, de RezendeLC, SilvaIV, RangelLB. Evaluation of the progesterone receptor status in breast cancer using three different antibodies: a comparison by Allred score system. Int J Clin Exp Pathol. 2013;7(1):331–339.24427354
   PubMed Web of Science ®Google Scholar
• ElstonCW, EllisIO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–410. doi:10.1111/j.1365-2559.1991.tb00229.x1757079
   PubMed Web of Science ®Google Scholar
• American Joint Committee on Cancer (AJCC). Cancer Staging Manual. 8th ed. Springer; 2016.
   Google Scholar
• DuffySW, TabárL, YenAM-F, et al. Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. Cancer. 2020;126(13):2971–2979. doi:10.1002/cncr.3285932390151
   PubMed Web of Science ®Google Scholar
• PataniN, KhaledY, Al ReefyS, MokbelK. Ductal carcinoma in-situ: an update for clinical practice. Surg Oncol. 2011;20(1):e23–e31. doi:10.1016/j.suronc.2010.08.00721106367
   PubMed Web of Science ®Google Scholar
• Chavez de Paz VillanuevaC, BonevV, SenthilM, et al. Factors associated with underestimation of invasive cancer in patients with ductal carcinoma in situ: precautions for active surveillance. JAMA Surg. 2017;152(11):1007–1014. doi:10.1001/jamasurg.2017.218128700803
   PubMed Web of Science ®Google Scholar
• MeursCJC, van RosmalenJ, Menke-PluijmersMBE, et al. A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers. Br J Cancer. 2018;119:1155–1162. doi:10.1038/s41416-018-0276-630327564
   PubMed Web of Science ®Google Scholar
• PageDL, SteelCM, DixonJM. ABC of breast disease. Carcinoma in situ and patients at high risk of breast cancer. Br Med J. 1995;310:39–42. doi:10.1136/bmj.310.6971.397827556
   PubMed Web of Science ®Google Scholar
• LymanGH, SomerfieldMR, BossermanLD, PerkinsCL, WeaverDL, GiulianoAE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(5):561–564. doi:10.1200/JCO.2016.71.094727937089
   PubMed Web of Science ®Google Scholar
• KaufmanSA, HarrisEE, BaileyL, et al. ACR appropriateness criteria(R) ductal carcinoma in situ. Oncology. 2015;29(6):446–458, 441–460.
   Web of Science ®Google Scholar
• National Breast Cancer Organization Netherlands (NABON). Evidence-based richtlijn Mammacarcinoom. Version 2.0.2012 Available from:http://www.oncoline.nl/. Assessed 920, 2020.
   Google Scholar
• HarnettA, SmallwoodJ, TitshallV, ChampionA; Guideline Development G. Diagnosis and treatment of early breast cancer, including locally advanced disease–summary of NICE guidance. BMJ. 2009;338:b438. doi:10.1136/bmj.b43819244302
   PubMed Web of Science ®Google Scholar
• ChehadeHEH, HeadonH, WazirU, AbtarH, KasemA, MokbelK. Is sentinel lymph node biopsy routinely indicated in patients with a diagnosis of ductal carcinoma in situ? A systematic literature review and meta-analysis. Am J Surg. 2017;213:171–180. doi:10.1016/j.amjsurg.2016.04.01927773373
   PubMed Web of Science ®Google Scholar
• LucciAJr, KelemenPR, MillerCIII, et al. National practice patterns of sentinel lymph node dissection for breast carcinoma. J Am Coll Surg. 2001;192:453–458. doi:10.1016/S1072-7515(01)00798-011294401
   PubMed Web of Science ®Google Scholar
• ParkHS, ParkS, ChoJ, et al. Risk predictors of underestimation and the need for sentinel node biopsy in patients diagnosed with ductal carcinoma in situ by preoperative needle biopsy. J Surg Oncol. 2013;107(4):388–392. doi:10.1002/jso.2327323007901
   PubMed Web of Science ®Google Scholar
• PriceA, SchnabelF, ChunJ, et al. Sentinel lymph node positivity in patients undergoing mastectomies for ductal carcinoma in situ (DCIS). Breast J. 2020;26(5):931–936. doi:10.1111/tbj.1373731957944
   PubMed Web of Science ®Google Scholar
• CollyarD, PintoD, StobartH, VerschuurE, van OirsouwM. How patient advocates and researchers work together in PRECISION* to identify low-risk ductal carcinoma in situ (DCIS) that may not need aggressive treatment. Cancer Res. 2020;80(4 Supplement):P1-16-04. doi:10.1158/1538-7445.SABCS19-P1-16-04
   Web of Science ®Google Scholar